JOP20190203A1 - بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها - Google Patents
بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامهاInfo
- Publication number
- JOP20190203A1 JOP20190203A1 JOP/2019/0203A JOP20190203A JOP20190203A1 JO P20190203 A1 JOP20190203 A1 JO P20190203A1 JO P20190203 A JOP20190203 A JO P20190203A JO P20190203 A1 JOP20190203 A1 JO P20190203A1
- Authority
- JO
- Jordan
- Prior art keywords
- methods
- binding proteins
- tigit antigen
- abps
- tigit
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
يتعلق الاختراع الحالي بتقديم بروتينات رابطة لمولد الضد (ABPs) ترتبط بشكل انتقائي بـ TIGIT والأشكال المتماثلة والمتشاكلة، وتركيبات تشتمل على بروتينات ABPs. كما يتم تقديم طرق لاستخدام بروتينات ABPs، مثل الطرق العلاجية والتشخيصية.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762479042P | 2017-03-30 | 2017-03-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
JOP20190203A1 true JOP20190203A1 (ar) | 2019-09-03 |
Family
ID=62002506
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2019/0203A JOP20190203A1 (ar) | 2017-03-30 | 2017-06-16 | بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها |
Country Status (15)
Country | Link |
---|---|
US (1) | US11453720B2 (ar) |
EP (1) | EP3601340A1 (ar) |
JP (1) | JP7335164B2 (ar) |
KR (1) | KR20190134605A (ar) |
CN (1) | CN110546163B (ar) |
AU (1) | AU2018243665A1 (ar) |
BR (1) | BR112019018378A2 (ar) |
CA (1) | CA3055289A1 (ar) |
CO (1) | CO2019009612A2 (ar) |
IL (1) | IL269074A (ar) |
JO (1) | JOP20190203A1 (ar) |
MX (1) | MX2019010440A (ar) |
PH (1) | PH12019502025A1 (ar) |
SG (1) | SG11201908092RA (ar) |
WO (1) | WO2018183889A1 (ar) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2018003898A (es) | 2015-10-01 | 2018-12-17 | Potenza Therapeutics Inc | Proteínas de unión al antígeno anti-tigit y métodos para usarlas. |
PL3618863T3 (pl) | 2017-05-01 | 2023-11-06 | Agenus Inc. | Przeciwciała anty- tigit i sposoby ich zastosowania |
CN112638944A (zh) | 2018-08-23 | 2021-04-09 | 西进公司 | 抗tigit抗体 |
GB201820006D0 (en) * | 2018-12-07 | 2019-01-23 | Lifearc | Humanised anti-IL17BR antibody |
EP4168118A1 (en) | 2020-06-18 | 2023-04-26 | Genentech, Inc. | Treatment with anti-tigit antibodies and pd-1 axis binding antagonists |
TW202216778A (zh) | 2020-07-15 | 2022-05-01 | 美商安進公司 | Tigit及cd112r阻斷 |
TW202304965A (zh) | 2021-05-04 | 2023-02-01 | 美商艾吉納斯公司 | 抗tigit抗體、抗cd96抗體及其使用方法 |
EP4341287A1 (en) * | 2021-05-18 | 2024-03-27 | Suzhou Kanova Biopharmaceutical Co., Ltd. | Anti-tigit antibodies and their use |
CN115466327A (zh) * | 2021-06-10 | 2022-12-13 | 北京天广实生物技术股份有限公司 | 结合tigit的抗体及其用途 |
TW202320848A (zh) | 2021-07-28 | 2023-06-01 | 美商建南德克公司 | 治療癌症之方法及組成物 |
WO2023056403A1 (en) | 2021-09-30 | 2023-04-06 | Genentech, Inc. | Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists |
WO2023240058A2 (en) | 2022-06-07 | 2023-12-14 | Genentech, Inc. | Prognostic and therapeutic methods for cancer |
Family Cites Families (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2 Inc | Geänderte antikörper. |
US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
ATE135397T1 (de) | 1988-09-23 | 1996-03-15 | Cetus Oncology Corp | Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
EP1997894B1 (en) | 1992-02-06 | 2011-03-30 | Novartis Vaccines and Diagnostics, Inc. | Biosynthetic binding protein for cancer marker |
DE69333082T2 (de) | 1992-02-11 | 2004-05-06 | Cell Genesys, Inc., Foster City | Erzielen von homozygotem durch zielgerichtete genetische ereignisse |
US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
CA2163345A1 (en) | 1993-06-16 | 1994-12-22 | Susan Adrienne Morgan | Antibodies |
US5534615A (en) | 1994-04-25 | 1996-07-09 | Genentech, Inc. | Cardiac hypertrophy factor and uses therefor |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
WO1998058964A1 (en) | 1997-06-24 | 1998-12-30 | Genentech, Inc. | Methods and compositions for galactosylated glycoproteins |
WO1999022764A1 (en) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
JP2002510481A (ja) | 1998-04-02 | 2002-04-09 | ジェネンテック・インコーポレーテッド | 抗体変異体及びその断片 |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
EP2261229A3 (en) | 1998-04-20 | 2011-03-23 | GlycArt Biotechnology AG | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
JP2003512019A (ja) | 1999-01-15 | 2003-04-02 | ジェネンテック・インコーポレーテッド | 変化したエフェクター機能を有するポリペプチド変異体 |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
ES2420835T3 (es) | 1999-04-09 | 2013-08-27 | Kyowa Hakko Kirin Co., Ltd. | Procedimiento para controlar la actividad de las moléculas inmunofuncionales |
US20080050809A1 (en) | 1999-09-28 | 2008-02-28 | Alejandro Abuin | Novel human kinases and polynucleotides encoding the same |
JP4668498B2 (ja) | 1999-10-19 | 2011-04-13 | 協和発酵キリン株式会社 | ポリペプチドの製造方法 |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
CA2953239A1 (en) | 2000-10-06 | 2002-04-18 | Kyowa Hakko Kirin Co., Ltd. | Antibody composition-producing cell |
EP2316940B1 (en) | 2000-12-18 | 2013-07-24 | Dyax Corp. | Focused libraries of genetic packages |
EP1423510A4 (en) | 2001-08-03 | 2005-06-01 | Glycart Biotechnology Ag | ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED CELL CYTOTOXICITY DEPENDENT OF ANTIBODIES |
ES2326964T3 (es) | 2001-10-25 | 2009-10-22 | Genentech, Inc. | Composiciones de glicoproteina. |
US20030215914A1 (en) | 2001-12-10 | 2003-11-20 | Erwin Houtzager | Structure for presenting desired peptide sequences |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
CA2476518A1 (en) | 2002-02-22 | 2003-09-04 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
US7193069B2 (en) | 2002-03-22 | 2007-03-20 | Research Association For Biotechnology | Full-length cDNA |
CA2481837A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Production process for antibody composition |
BR0309145A (pt) | 2002-04-09 | 2005-02-01 | Kyowa Hakko Kogyo Kk | Células das quais o genoma é modificado |
CA2481920A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Antibody composition-containing medicament |
ATE503829T1 (de) | 2002-04-09 | 2011-04-15 | Kyowa Hakko Kirin Co Ltd | Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins |
AU2003236019A1 (en) | 2002-04-09 | 2003-10-20 | Kyowa Hakko Kirin Co., Ltd. | Drug containing antibody composition appropriate for patient suffering from Fc Gamma RIIIa polymorphism |
WO2003085119A1 (fr) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Procede d'amelioration de l'activite d'une composition d'anticorps de liaison avec le recepteur fc$g(g) iiia |
WO2004024068A2 (en) | 2002-09-11 | 2004-03-25 | Genentech, Inc. | Novel composition and methods for the treatment of immune related diseases |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
PL212899B1 (pl) | 2002-12-16 | 2012-12-31 | Genentech Inc | Humanizowane przeciwcialo, kompozycja zawierajaca to przeciwcialo, wyrób fabryczny, przeciwcialo lub jego fragment do zastosowania w sposobie indukowania apoptozy, izolowany kwas nukleinowy, wektor ekspresji, komórka gospodarza, sposób wytwarzania przeciwciala lub jego fragmentu, plynny preparat i zastosowanie przeciwciala do wytwarzania leku |
US8716254B2 (en) | 2003-03-24 | 2014-05-06 | The Scripps Research Institute | DNA vaccines against tumor growth and methods of use thereof |
CA2542046A1 (en) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | Fused protein composition |
CA2542125A1 (en) | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | Process for producing antibody composition by using rna inhibiting the function of .alpha.1,6-fucosyltransferase |
HUE031632T2 (en) | 2003-11-05 | 2017-07-28 | Roche Glycart Ag | Antigen binding molecules with enhanced Fc receptor binding affinity and effector function |
JPWO2005053742A1 (ja) | 2003-12-04 | 2007-06-28 | 協和醗酵工業株式会社 | 抗体組成物を含有する医薬 |
EP2360186B1 (en) | 2004-04-13 | 2017-08-30 | F. Hoffmann-La Roche AG | Anti-P-selectin antibodies |
TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
NZ580115A (en) | 2004-09-23 | 2010-10-29 | Genentech Inc | Cysteine engineered antibody light chains and conjugates |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
JP2008544746A (ja) | 2005-05-12 | 2008-12-11 | ザイモジェネティクス, インコーポレイテッド | 免疫応答を調節するための組成物および方法 |
WO2006138739A2 (en) | 2005-06-17 | 2006-12-28 | Tolerx, Inc. | Ilt3 binding molecules and uses therefor |
EP1963534A2 (en) | 2005-12-19 | 2008-09-03 | Genizon Biosciences Inc. | Genemap of the human gene associated with crohn's disease |
US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
PL2170959T3 (pl) | 2007-06-18 | 2014-03-31 | Merck Sharp & Dohme | Przeciwciała przeciwko ludzkiemu receptorowi programowanej śmierci PD-1 |
AU2008298603B2 (en) | 2007-09-14 | 2015-04-30 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
DK2279412T3 (en) | 2008-04-09 | 2017-10-16 | Genentech Inc | PRESENT UNKNOWN COMPOSITIONS AND PROCEDURES FOR TREATING IMMUNRATED DISEASES |
MX2012006626A (es) | 2009-12-22 | 2012-06-25 | Hoffmann La Roche | Agregacion dependiente de secuencia. |
EP2388336A1 (en) | 2010-05-19 | 2011-11-23 | Signature Diagnostics AG | Method and kits for diagnosing colorectal cancer |
CN103168048B (zh) | 2010-06-09 | 2017-02-15 | 酶原遗传学有限公司 | 二聚vstm3融合蛋白和相关的组合物和方法 |
US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
DK2593594T3 (en) | 2010-07-16 | 2017-12-11 | Adimab Llc | ANTIBODY LIBRARIES |
PL2632927T3 (pl) | 2010-10-26 | 2016-09-30 | Boroniany jako inhibitory arginazy | |
DE102011005235B4 (de) | 2011-03-08 | 2017-05-24 | Sirs-Lab Gmbh | Verfahren zum Identifizieren einer Teilmenge von Polynucleotiden aus einer dem Humangenom entsprechenden Ausgangsmenge von Polynucleotiden zur in vitro Bestimmung eines Schweregrads der Wirtsantwort eines Patienten |
EP3501550A1 (en) | 2012-04-02 | 2019-06-26 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with human disease |
EP2858673A4 (en) | 2012-06-06 | 2016-06-22 | Oncomed Pharm Inc | BINDING AGENTS MODULATING THE HIPPO SIGNALING PATH AND USES THEREOF |
WO2014058915A2 (en) | 2012-10-08 | 2014-04-17 | St. Jude Children's Research Hospital | Therapies based on control of regulatory t cell stability and function via a neuropilin-1:semaphorin axis |
EP3508215A3 (en) | 2012-12-03 | 2019-10-02 | Bristol-Myers Squibb Company | Enhancing anti-cancer activity of immunomodulatory fc fusion proteins |
NZ709059A (en) | 2012-12-04 | 2016-11-25 | Oncomed Pharm Inc | Immunotherapy with binding agents |
EP2991679A4 (en) | 2013-04-29 | 2016-12-07 | Adimab Llc | POLYSPECIFIC REAGENTS, PROCESS FOR THEIR PREPARATION AND USE |
KR20160030936A (ko) * | 2013-07-16 | 2016-03-21 | 제넨테크, 인크. | Pd-1 축 결합 길항제 및 tigit 억제제를 사용한 암을 치료하는 방법 |
TN2017000024A1 (en) | 2014-08-19 | 2018-07-04 | Merck Sharp & Dohme | Anti-tigit antibodies. |
RU2017119428A (ru) | 2014-11-06 | 2018-12-06 | Дженентек, Инк. | Комбинированная терапия, включающая применение агонистов, связывающихся с ох40, и ингибиторов tigit |
TN2017000267A1 (en) | 2014-12-23 | 2018-10-19 | Bristol Myers Squibb Co | Antibodies to tigit |
TWI715587B (zh) * | 2015-05-28 | 2021-01-11 | 美商安可美德藥物股份有限公司 | Tigit結合劑和彼之用途 |
JP6861418B2 (ja) * | 2015-09-02 | 2021-04-28 | イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム リミテッド | ヒトt細胞免疫グロブリン及びitimドメイン(tigit)に特異的な抗体 |
CN106554347B (zh) | 2015-09-25 | 2020-10-30 | 浙江博生医药有限公司 | Egfr激酶抑制剂及其制备方法和应用 |
MX2018003898A (es) | 2015-10-01 | 2018-12-17 | Potenza Therapeutics Inc | Proteínas de unión al antígeno anti-tigit y métodos para usarlas. |
-
2017
- 2017-06-16 JO JOP/2019/0203A patent/JOP20190203A1/ar unknown
-
2018
- 2018-03-30 WO PCT/US2018/025460 patent/WO2018183889A1/en active Application Filing
- 2018-03-30 AU AU2018243665A patent/AU2018243665A1/en active Pending
- 2018-03-30 BR BR112019018378A patent/BR112019018378A2/pt unknown
- 2018-03-30 US US16/498,520 patent/US11453720B2/en active Active
- 2018-03-30 KR KR1020197026053A patent/KR20190134605A/ko not_active Application Discontinuation
- 2018-03-30 CA CA3055289A patent/CA3055289A1/en active Pending
- 2018-03-30 JP JP2019548287A patent/JP7335164B2/ja active Active
- 2018-03-30 EP EP18718377.7A patent/EP3601340A1/en active Pending
- 2018-03-30 CN CN201880016245.XA patent/CN110546163B/zh active Active
- 2018-03-30 MX MX2019010440A patent/MX2019010440A/es unknown
- 2018-03-30 SG SG11201908092R patent/SG11201908092RA/en unknown
-
2019
- 2019-09-02 IL IL26907419A patent/IL269074A/en unknown
- 2019-09-04 CO CONC2019/0009612A patent/CO2019009612A2/es unknown
- 2019-09-05 PH PH12019502025A patent/PH12019502025A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
MX2019010440A (es) | 2020-02-07 |
KR20190134605A (ko) | 2019-12-04 |
CA3055289A1 (en) | 2018-10-04 |
RU2019127786A (ru) | 2021-04-30 |
JP2020512973A (ja) | 2020-04-30 |
RU2019127786A3 (ar) | 2021-07-22 |
IL269074A (en) | 2019-11-28 |
US20200095324A1 (en) | 2020-03-26 |
PH12019502025A1 (en) | 2020-06-01 |
EP3601340A1 (en) | 2020-02-05 |
WO2018183889A1 (en) | 2018-10-04 |
US11453720B2 (en) | 2022-09-27 |
SG11201908092RA (en) | 2019-10-30 |
JP7335164B2 (ja) | 2023-08-29 |
BR112019018378A2 (pt) | 2020-04-07 |
CN110546163A (zh) | 2019-12-06 |
CN110546163B (zh) | 2024-03-29 |
CO2019009612A2 (es) | 2020-01-17 |
AU2018243665A1 (en) | 2019-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12018500714A1 (en) | Anti-tigit antigen-binding proteins and methods of use thereof | |
PH12020500240A1 (en) | Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies | |
PH12019502025A1 (en) | Anti-tigit antigen-binding proteins and methods of use thereof | |
PH12019501405A1 (en) | Anti-neuropilin antigen-binding proteins and methods of use thereof | |
WO2017087901A3 (en) | Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies | |
WO2016077397A3 (en) | Anti-pd-1 antibodies, compositions comprising anti-pd-1 antibodies and methods of using anti-pd-1 antibodies | |
PH12021550690A1 (en) | Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies | |
MX2018014154A (es) | Polinucleotidos moduladores. | |
MX2017013562A (es) | Reguladores de microbioma y usos relacionados de los mismos. | |
WO2016014434A3 (en) | Anti-cd74 antibodies, compositions comprising anti-cd74 antibodies and methods of using anti-cd74 antibodies | |
EA201791485A1 (ru) | Анти-cd47-антитела и их применения | |
MX2017006217A (es) | Polinucleotidos moduladores. | |
MY191944A (en) | Binding proteins and methods of use thereof | |
MX2019005821A (es) | Proteínas de unión a antígenos anti-gitr y métodos de uso de las mismas. | |
MX2021007692A (es) | Proteinas de union anti-pd-1 y metodos de uso de las mismas. | |
MX2017003211A (es) | Anticuerpos anti-met y composiciones. | |
MX2021007848A (es) | Proteinas de union a anti-ctla-4 y metodos de uso de las mismas. | |
PH12018501279A1 (en) | Compositions comprising 15-hepe and methods of using the same | |
NZ715582A (en) | Lectin-like oxidized ldl receptor 1 antibodies and methods of use | |
MX2022002635A (es) | Anticuerpos anti proteina similar a angiopoyetina 4 y metodos de uso. | |
TW201613977A (en) | Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use | |
PH12019502694A1 (en) | Anti-trkb antibodies | |
MX2021007846A (es) | Proteinas que se unen a anti-pd-l1 y metodos de uso de las mismas. | |
MX2022015948A (es) | Proteínas de unión anti-ctla-4 y métodos de uso de estas. | |
WO2018129451A3 (en) | Anti-fgfr antibodies and methods of use |